• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
MLN8237

MLN8237

Product ID M4652
Cas No. 1028486-01-2
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $118.00 In stock
5 mg $219.00 In stock
10 mg $337.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

MLN8237 inhibits aurora kinase A (AurA) preventing mitotic spindle formation and proper completion of mitosis. MLN8237 exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for multiple myeloma, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia (CLL). In bladder cancer cells, MLN8237 induces cell cycle arrest, aneuploidy, and apoptosis; in animal models of bladder cancer, this compound inhibits tumor growth. Additionally, MLN8237 inhibits tumor growth of neuroblastomas in vivo as well. In HUVECs, MLN8237 decreases tubule formation and inhibits VEGF secretion, suggesting potential anti-angiogenic activity.

Product Info

Cas No.

1028486-01-2

Purity

≥98%

Formula

C27H20ClFN4O4

Formula Wt.

518.92

IUPAC Name

4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid

Synonym

Alisertib

Solubility

DMSO 27 mg/mL (52.03 mM) Water Insoluble Ethanol Insoluble

Appearance

Pale Yellow Powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

M4652 MSDS PDF

Info Sheet

M4652 Info Sheet PDF

References

Romain C, Paul P, Kim KW, et al. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma. J Pediatr Surg. 2014 Jan;49(1):159-65. PMID: 24439602.

Kelly KR, Shea TC, Goy A, et al. Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2013 Dec 20. [Epub ahead of print]. PMID: 24352795.

Zhou N, Singh K, Mir MC, et al. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res. 2013 Apr 1;19(7):1717-28. PMID: 23403633.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • A3080

    AHU-377 Tris Salt

    LBQ657 prodrug; neprilysin inhibitor.

    ≥99%
  • M1575

    7-Methyl-6-mercaptopurine

    Thiopurine antimetabolite; PRPP amidotransferas...

    ≥87%
  • I5034

    Imiquimod

    Imidazoquinoline nucleoside analog; TLR-7/8 ago...

    ≥99.5%
  • H9612

    Hydrocortisone 21-Acetate

    Steroid hormone involved in stress signaling; g...

    ≥98%
  • V3276

    Vitamin E, Natural

    Antioxidant.

    ≥97%
  • M3379

    Mitoxantrone Dihydrochloride

    Anthracenedione, DNA intercalator; Pim-1 inhibi...

    ≥98%
  • G2873

    Growth Hormone Releasing Factor, sheep

    Endogenous peptide hormone, involved in growth ...

    ≥95%
  • T7132

    Triacetyl Resveratrol

    Resveratrol prodrug; potential SIRT1 activator....

    ≥99%
  • R2815

    Recombinant HIV-1 “0” group consensus

    Recombinant HIV-1 antigen fragment.

    ≥95%
  • S5722

    Sofosbuvir

    Viral RNA polymerase inhibitor.

    ≥98%
  • F1853

    Fenofibrate

    Fibrate; PPARα agonist.

    ≥98%
  • G3357

    Ginkgolide C

    Diterpene lactone found in Ginkgo; GABA-A, α-1...

    ≥98%
  • C4535

    Clinafloxacin Hydrochloride

    Fluoroquinolone; topoisomerase IV and bacterial...

    ≥98%
  • A6825

    L-Arginine

    Endogenous amino acid, also found in meat, dair...

    ≥98%
  • T0393

    (+/-)-Taxifolin Hydrate

    Catechol-type flavonoid.

    ≥95%
  • K1650

    Kemptide

    PKA substrate.

    ≥95%
  • A0001

    A-803467

    Nav1.8 Na+ channel blocker, potential Nav1.5 Na...

    ≥97%
  • A9602

    Azacitidine

    Nucleoside (cytidine) analog; DNMT inhibitor, p...

    ≥98%
  • D490280

    DMH-1

    Inhibitor of BMP.

    ≥99%
  • A5072

    Amsacrine

    Acridine derivative, DNA intercalator; topoisom...

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2026 LKT Laboratories, All Rights Reserved - Products for research use only